Interpreting outcome data in hematological malignancies: a paradigm for clinical studies - Wikidata - awgldk - TriplyDB

Interpreting outcome data in hematological malignancies: a paradigm for clinical studies

Interpreting outcome data in hematological malignancies: a paradigm for clinical studies

http://www.wikidata.org/entity/Q30658847

about

Interpreting outcome data in hematological malignancies: a paradigm for clinical studies

http://www.wikidata.org/entity/Q30658847

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Interpreting outcome data in hematological malignancies: a paradigm for clinical studies

@ast

Interpreting outcome data in hematological malignancies: a paradigm for clinical studies

@en

type

label

Interpreting outcome data in hematological malignancies: a paradigm for clinical studies

@ast

Interpreting outcome data in hematological malignancies: a paradigm for clinical studies

@en

prefLabel

Interpreting outcome data in hematological malignancies: a paradigm for clinical studies

@ast

Interpreting outcome data in hematological malignancies: a paradigm for clinical studies

@en

P1433

Q30658847-13CC246B-B8FF-4834-888E-12FF55910D4E

P1476

Q30658847-E905FB68-6CD0-494E-9D11-AC9B5D31B9BB

P2093

Q30658847-26DD544A-9739-4C72-8EAD-3B75F2E4272E

P2860

Q30658847-081662B1-ACE4-43CF-8000-CD6D99BD0840

Q30658847-154AEF50-5FDF-4E1F-9941-84A10F45E7AC

Q30658847-24ABAC44-16AF-40F4-B912-FC2394AD0E9C

Q30658847-2BF1CF43-70D1-4B06-AE61-7B832C8C598A

Q30658847-4322BA20-427E-48CC-AAED-19040E6BA74E

Q30658847-61D523B7-2D22-40BB-9E00-A58C0AC5CE20

Q30658847-6B50CAB8-D8B3-40B5-AC28-33DC19511815

Q30658847-74FA23FF-8EBD-41BF-8C33-791CDC69EB72

Q30658847-8029F205-00AD-4585-AAC0-21967008D0C5

Q30658847-8DE32196-4567-490D-ADA5-981ED48B0E98

P304

Q30658847-2669679E-F838-4814-A16D-D68B7F96AB3B

P31

Q30658847-7EDFC102-5F39-46C7-B676-A46CF7EE0885

P356

Q30658847-97D808C0-80FC-41E8-9049-B1D1B71D45E4

P407

Q30658847-E6488D3F-5BA8-4B62-9766-5FF19FBB7556

P433

Q30658847-0DB5A181-5E0E-4955-923D-4FDAAE60B896

P478

Q30658847-CC61576C-B4B1-4678-BECD-F27A756A392F

P577

Q30658847-83959BA1-96DE-47F1-846F-6ED5E272E6D9

P698

Q30658847-B802462D-81E6-423C-84F9-94588DBA9BF0

P932

Q30658847-36B5A402-6CDF-469B-80B2-C87AEB1CE4EE

P356

P1433

Rambam Maimonides Medical Journal

P1476

Interpreting outcome data in hematological malignancies: a paradigm for clinical studies

@en

P2093

Jacob M Rowe

http://www.w3.org/2001/XMLSchema#string

P2860

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Anthracycline dose intensification in acute myeloid leukemia.

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

The myth of the second remission of acute leukemia in the adult.

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.

P304

e0004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5041/RMMJ.10104

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23908854

http://www.w3.org/2001/XMLSchema#string

P932

3678915

http://www.w3.org/2001/XMLSchema#string